SynthesisFrontiers in immunology2026
Anti-mGluR5 encephalitis: distinctive clinical features and antibody patterns in the Chinese population.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-metabotropic glutamate receptor 5 (mGluR5) encephalitis is a rare subtype of autoimmune encephalitis, most often associated with Hodgkin's lymphoma, and accounts for less than 1% of reported cases worldwide. Current knowledge is primarily based on isolated reports from Western populations, with limited data from Asia. The clinical spectrum, tumor associations, and antibody detection patterns in Chinese patients remain poorly understood. Methods: We retrospectively reviewed eight consecutive patients with anti-mGluR5 encephalitis diagnosed at a single tertiary referral center between October 2019 and March 2025. Demographic, clinical, neuroimaging, antibody testing, treatment, and outcome data were analyzed. In addition, a systematic review of the Chinese literature identified 31 previously reported cases. Combined institutional and literature cases (n = 39) were summarized and contextualized within the existing international literature. Results: The age at onset was 42.5 ± 19.7 years (range: 7-78), with a male-to-female ratio of 8:5. Cognitive impairment (61.5%) was the most frequent presenting feature, followed by behavioral disturbances (53.8%) and seizures (53.8%). Tumors were identified in only 7.7% of Chinese patients, notably lower than the 61.5% reported in international literature, with Hodgkin's lymphoma rarely observed in this population. Serum anti-mGluR5 antibodies were detected in all tested patients, while cerebrospinal fluid positivity was observed in 42.4% of paired samples. First-line immunotherapy (steroids, intravenous immunoglobulin, or plasma exchange) led to clinical improvement in most patients, with 89.5% achieving a favorable outcome (Modified Rankin Scale ≤ 2) at last follow-up. Decreased consciousness at onset was significantly associated with a poorer prognosis (p = 0.009). Conclusions: Chinese patients with anti-mGluR5 encephalitis exhibit distinctive clinical and immunological features, particularly in terms of tumor associations and antibody detection patterns. These findings expand our understanding of population-specific characteristics in anti-mGluR5 encephalitis and underscore the need for tailored diagnostic strategies and early immunotherapy to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.